|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered NX-019 in Patients With Advanced, EGFR Mutant Cancer
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.
100 项与 Nalo Therapeutics, Inc. 相关的临床结果
0 项与 Nalo Therapeutics, Inc. 相关的专利(医药)
100 项与 Nalo Therapeutics, Inc. 相关的药物交易
100 项与 Nalo Therapeutics, Inc. 相关的转化医学